Edition:
India

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

37.91USD
18 Oct 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$37.91
Open
$37.77
Day's High
$38.45
Day's Low
$37.31
Volume
136,471
Avg. Vol
141,258
52-wk High
$53.90
52-wk Low
$22.23

Ho, Tony 

Dr. Tony Ho M.D. serves as Executive Vice President - Research and Development at CRISPR Therapeutics Ltd. Prior to joining our company, Dr. Ho held a number of roles at AstraZeneca between 2012 and 2017, where he most recently was Senior Vice President and Head of Oncology Integration and Innovation. Before that, he was Vice President and Global Medicine Leader, where he led the development and commercialization of two key drugs for AstraZeneca – Lynparza, a PARP inhibitor for ovarian cancer and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug for bladder cancer. Prior to joining AstraZeneca, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. Earlier in his career, Dr. Ho was the co-founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company. Dr. Ho completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine.

Basic Compensation

Total Annual Compensation, USD 673,301
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,475,810
Fiscal Year Total, USD 4,149,120

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Rodger Novak

645,572

Samarth Kulkarni

9,727,530

Michael Tomsicek

2,253,360

Tony Ho

4,149,120

James Kasinger

3,160,750

Lawrence Klein

--
As Of  31 Dec 2018